866-997-4948(US-Canada Toll Free)

Lung Transplantation - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Jan 2014

Category :

Biotechnology

No. of Pages : 44 Pages


Global Markets Directs, \'Lung Transplantation Pipeline Review, H1 2014\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Lung Transplantation Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Lung Transplantation.
  • A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Lung Transplantation pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Lung Transplantation.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Lung Transplantation pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lung Transplantation Overview 6
Therapeutics Development 7
Pipeline Products for Lung Transplantation - Overview 7
Pipeline Products for Lung Transplantation - Comparative Analysis 8
Lung Transplantation - Therapeutics under Development by Companies 9
Lung Transplantation - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Lung Transplantation - Companies Involved in Therapeutics Development 12
Quark Pharmaceuticals, Inc. 12
Vectura Group plc 13
Proteo, Inc. 14
APT Pharmaceuticals, Inc. (Inactive) 15
Neopharm Ltd. 16
Lung Transplantation - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Assessment by Therapeutic Class 26
Drug Profiles 28
cyclosporine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
EZ-2053 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Elafin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Respiratory and Inflammatory Diseases Program - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
VR-909 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Lung Transplantation - Recent Pipeline Updates 36
Lung Transplantation - Product Development Milestones 39
Featured News & Press Releases 39
Aug 22, 2013: Drug Application Filed for Additional Form of Immunosuppressant, Cellcept Powder for Oral Suspension 32% 39
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 39
May 16, 2011: Chugai Pharma Files Application Seeking Japanese Approval For Pediatric Dosage And Administration Of CellCept 40
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA 41
Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 41
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans 42

Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Table


Number of Products under Development for Lung Transplantation, H1 2014 7
Number of Products under Development for Lung Transplantation - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Lung Transplantation - Pipeline by Quark Pharmaceuticals, Inc., H1 2014 12
Lung Transplantation - Pipeline by Vectura Group plc, H1 2014 13
Lung Transplantation - Pipeline by Proteo, Inc., H1 2014 14
Lung Transplantation - Pipeline by APT Pharmaceuticals, Inc. (Inactive), H1 2014 15
Lung Transplantation - Pipeline by Neopharm Ltd., H1 2014 16
Assessment by Monotherapy Products, H1 2014 17
Number of Products by Stage and Target, H1 2014 19
Number of Products by Stage and Mechanism of Action, H1 2014 21
Number of Products by Stage and Route of Administration, H1 2014 23
Number of Products by Stage and Molecule Type, H1 2014 25
Number of Products by Stage and Therapeutic Class, H1 2014 27
Lung Transplantation Therapeutics - Recent Pipeline Updates, H1 2014 36

List of Chart


Number of Products under Development for Lung Transplantation, H1 2014 7
Number of Products under Development for Lung Transplantation - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 17
Number of Products by Top 10 Target, H1 2014 18
Number of Products by Stage and Top 10 Target, H1 2014 19
Number of Products by Top 10 Mechanism of Action, H1 2014 20
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 21
Number of Products by Top 10 Route of Administration, H1 2014 22
Number of Products by Stage and Top 10 Route of Administration, H1 2014 23
Number of Products by Top 10 Molecule Type, H1 2014 24
Number of Products by Stage and Top 10 Molecule Type, H1 2014 25
Number of Products by Top 10 Therapeutic Class, H1 2014 26
Number of Products by Stage and Top 10 Therapeutic Class, H1 2014 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *